Funding has been secured to develop a drug-device combination that was said to potentially revolutionise how individual cells are monitored and treated in patients with immune-related diseases.
Research was led by the National Institute for Health and Care Research (NIHR), Moorfields Eye Hospital, UCL Institute of Ophthalmology, and Birmingham Biomedical Research Centres.
Dr Colin Chu, lead investigator and clinical academic ophthalmologist at UCL and Moorfields, said: ‘The immune system plays a crucial role in nearly every known disease. However, imaging and tracking individual immune cells directly in patients remains a significant challenge. By overcoming this, we hope to unlock transformative advances relevant to many other systemic conditions, such as autoimmunity, infections and cardiovascular diseases.’
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here
